NCNoll L. Campbell

Noll L. Campbell

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Noll L. Campbell has a total of 109 co-authors. Here are the top co-authors by number of shared publications:

  • Malaz A. Boustani

    Indiana University Center for Aging Research, Regenstrief Institute, Inc, Indianapolis, USA

    11 shared publications
  • Richard J. Holden

    Indiana University Bloomington, USA

    6 shared publications
  • Sujuan Gao

    Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, USA

    6 shared publications
  • Jordan R. Hill

    Department of Health & Wellness Design, School of Public Health - Bloomington, Indiana University, 1025 E 7th St, Bloomington, IN, 47405, United States, 1 812-856-5032

    5 shared publications
  • Alan J. Zillich

    Department of Pharmacy Practice, College of Pharmacy, Purdue University, 575 Stadium Mall Drive, West Lafayette, IN 47907, USA

    3 shared publications
  • Anthony J. Perkins

    Indiana University Center for Health Innovation and Implementation Science and Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana

    3 shared publications

Latest Publications

  • Open Access

    Developing mHealth IT for Older Adult Medication Safety: Remote Participatory Co-Design Using the RAPID Method

    by Jordan R Hill, Aaron Ganci, Noll L Campbell, Andrew C Pickett, Michelle A Chui, Ephrem Abebe, Richard J Holden

    Background: Participatory co-design is a design approach that involves end users in intervention design and its use in health care applications has become widespread. Traditionally, co-design has been conducted in person in a laboratory-based setting; however, it has recently shifted to being performed remotely. Remote co-design has the potential to overcome some of the limitations of traditional in-person approaches, including expanding a study’s geographic reach, recruiting participants from underrepresented groups, reducing power imbalances between researchers and participants, and enhancing engagement through online tools. Given these benefits, further reporting and refinement of remote co-design methods are needed. Objective: This paper’s objective is to present our Remote and Accessible Participatory Intervention Design (RAPID) method and discuss the choices and challenges we encountered adapting participatory co-design for remote use. Methods: We adapted our previously developed 5-step in-person participatory co-design method for health intervention design. To apply the adapted co-design method, we recruited 2 groups of 5 participants (one of older adult pharmacy patients and the other of pharmacy staff) to design a digital kiosk for use by older adults to promote safe over-the-counter medication purchases in retail pharmacies. Results: Adaptations made to the co-design process were classified under the following categories: facilitation; collaboration, communication, and sensemaking; accessibility and universality; tangible tools and games; and research compliance. Anecdotally, the remote co-design process took longer when compared to in person due to shorter sessions and between-session refinement, but it allowed for flexible scheduling and makeup sessions when required. Conclusions: Our RAPID method offers an approach to remote co-design that other teams can implement or adapt to their needs. Our experiences with RAPID identify certain drawbacks to remote co-design; however, these are balanced by advantages in convenience and flexibility.

  • Open Access

    Creating User Personas to Represent the Needs of Dementia Caregivers Who Support Medication Management at Home: Persona Development and Qualitative Study

    by Anna Jolliff, Priya Loganathar, Richard J Holden, Anna Linden, Himalaya Patel, Jessica R Lee, Aaron Ganci, Noll Campbell, Malaz Boustani, Nicole E Werner

    Background: Caregiver-assisted medication management plays a critical role in promoting medication adherence and quality of life for people living with Alzheimer disease or related dementias (ADRD). The current landscape of digital and nondigital interventions to support medication management does not meet caregivers’ needs, contexts, and levels of technological proficiency. Intervention development can be facilitated using personas or data-driven archetypes that represent end users’ traits relevant to solution design. Objective: This study aims to understand the strategies and unmet needs of ADRD caregivers who manage medications and use this understanding to create personas that can inform customized caregiver interventions. Methods: Participants were self-identified primary caregivers of people with ADRD living with or near the care recipient. Virtual contextual inquiry was completed in three stages: (1) enrollment interview, (2) virtual observation over a 1-week period, and (3) postobservation interview. Codebook thematic analysis of interview transcripts was used to identify dimensions of caregivers’ approaches to medication management. A reflexive, team-based affinity diagramming approach was used to identify attributes within these dimensions and group attributes into personas. Results: Participants (N=25) were aged 62.32 (SD 11.86) years on average, and 17 (68%) of them were female. Caregivers varied across 6 dimensions relevant to medication management: strategies for medication acquisition, medication storage and organization, medication administration, monitoring the care recipient for symptoms, communication with care network regarding medication, and acquiring information about medication. Three personas were created to represent the observed strategies, unmet needs, and levels of technology use related to medication management: Checklist Cheryl, in Control; Social Sam, Keeps it Simple; and Responsive Rhonda, Stays Relaxed. Conclusions: Caregivers in this study demonstrated a range of characteristics and values that informed their approach to medication management. They used a combination of technology-based strategies and strategies situated in their physical environments to manage medications. The personas created can be used to inform interventions, such as digital tools, that address caregivers’ unmet needs.


  • Open Access

    Deprescribing anticholinergics to preserve brain health: reducing the risk of dementia through deprescribing (R2D2): study protocol for a randomized clinical trial

    by Noll L. Campbell, Richard J. Holden, Sujuan Gao, Frederick W. Unverzagt, Kathleen A. Lane, Allie Carter, Addison B. Harrington, Sneha Manoharan, Neha Manoharan, Danielle L. Rosenthal, et al.

    Background: Older adults commonly experience chronic medical conditions and are at risk of cognitive impairment as a result of age, chronic comorbidity, and medications prescribed to manage multiple chronic conditions. Anticholinergic medications are common treatments for chronic conditions and have been repeatedly associated with poor cognitive outcomes, including delirium and dementia, in epidemiologic studies. However, no study has definitively evaluated the causal relationship between anticholinergics and cognition in a randomized controlled trial design. Utilizing our prior experience in deprescribing anticholinergic medications in various clinical environments, we designed an outpatient deprescribing intervention to prospectively test the potential causal relationship between anticholinergics and cognition in primary care older adults. Methods: This cluster randomized clinical trial will be conducted to evaluate the impact of an anticholinergic deprescribing intervention compared to usual care on outcomes of cognition and safety in primary care older adults. Participants will include those aged 65 years and over, receiving primary care in the greater Indianapolis area, using a strong anticholinergic within the last 2 weeks or with evidence of high-risk exposure in the past year. Those excluded will have a diagnosis of Alzheimer’s disease or related dementia, or serious mental illness. The trial plans to enroll 344 participants who will be cluster-randomized at the level of primary care physician to avoid contamination. Participants will complete outcome assessments every 6 months up to 2 years by blinded outcome assessors. The primary outcome of the study is a composite measure of cognition that includes domains assessing executive cognitive function, language, and memory. Secondary outcomes include patient-reported measures of pain intensity, depression, anxiety, sleep disturbance, and health-related quality of life. Discussion: The R2D2 trial will be the largest and longest prospective randomized trial testing the impact of an anticholinergic-specific deprescribing intervention on cognition in primary care older adults. Results could influence deprescribing methodology and provide new insight on the relationship between anticholinergics and cognition. Trial registration: ClinicalTrials.gov NCT04270474. Registered on February 17, 2020.


  • Open Access

    Deprescribing Anticholinergics to Preserve Brain Health: Reducing the Risk of Dementia through Deprescribing (R2D2): Study Protocol for a Randomized Clinical Trial

    by Noll L. Campbell, Richard J. Holden, Sujuan Gao, Frederick W. Unverzagt, Kathleen A. Lane, Allie Carter, Addison B. Harrington, Sneha Manoharan, Neha Manoharan, Danielle L. Rosenthal, et al.

    Background: Older adults commonly experience chronic medical conditions and are at risk of cognitive impairment as a result of age, chronic comorbidity, and medications prescribed to manage multiple chronic conditions. Anticholinergic medications are common treatments for chronic conditions, and have been repeatedly associated with poor cognitive outcomes, including delirium and dementia, in epidemiologic studies. However, no study has definitively evaluated the causal relationship between anticholinergics and cognition in a randomized controlled trial design. Utilizing our prior experience in deprescribing anticholinergic medications in various clinical environments, we designed an outpatient deprescribing intervention to prospectively test the potential causal relationship between anticholinergics and cognition in primary care older adults. Methods: This cluster randomized clinical trial will be conducted to evaluate the impact of an anticholinergic deprescribing intervention compared to usual care on outcomes of cognition and safety in primary care older adults. Participants will include those aged 65 years and over, receiving primary care in the greater Indianapolis area, using a strong anticholinergic within the last two weeks or with evidence of high-risk exposure in the past year. Those excluded will have a diagnosis of Alzheimer’s disease or related dementia, or serious mental illness. The trial plans to enroll 344 participants who will be cluster-randomized at the level of primary care physician to avoid contamination. Participants will complete outcome assessments every six months up to 2 years by blinded outcome assessors. The primary outcome of the study is a composite measure of cognition that includes domains assessing executive cognitive function, language, and memory. Secondary outcomes include patient-reported measures of pain intensity, depression, anxiety, sleep disturbance, and health-related quality of life. Discussion: The R2D2 trial will be the largest and longest prospective randomized trial testing the impact of an anticholinergic-specific deprescribing intervention on cognition in primary care older adults. Results could influence deprescribing methodology and provide new insight on the relationship between anticholinergics and cognition. Trial Registration: Trial Registration: clinicaltrials.gov, NCT04270474. Registered17 February 2020.

  • An Improved Statistical Modeling Approach to Individual Anticholinergic Drug Use Trend Analysis

    by Zhouyang Lou, Mingyang Li, Nan Kong, Noll L. Campbell, Wanzhu Tu

    Anticholinergic (AC) drugs are commonly prescribed to older adults for treating diseases and chronic conditions, such as chronic obstructive pulmonary disease, urinary incontinence, gastrointestinal disorder, or simply pain and allergy. The high prevalence of AC drug use can have a detrimental effect on the mental health of older adults. We aim to improve the prediction of future trends of AC drug use at the individual level, with pharmacy refill data. The individual drug use data presents challenges in the modeling, such as data being discrete-valued with excess zeros and having significant unobserved heterogeneity in the trend pattern. To address these challenges, we propose a statistical model of hierarchical structure and an EM scheme for the model parameter estimation. We evaluate the proposed modeling approach through a numerical study with synthetic data and a case study with real-world pharmacy refill data. The simulation study show that our analysis method outperforms the existing ones (e.g., reducing MSE significantly), particularly in terms of accurately predicting the trend pattern. The real-world case study further verifies the out-performance and demonstrate the advantageous features of our method. We expect the prediction tool developed based on our study can assist pharmacists' decision on initiating or strengthening behavioral interventions with the hope of discontinuing AC drug misuse.


  • Open Access

    Lessons Learned from a Shared Curriculum on Tobacco Cessation Using a Mixed-Methods Approach

    by Nervana Elkhadragy, Robin L. Corelli, Noll L. Campbell, Alan J. Zillich, Karen Suchanek Hudmon

    Although the sharing of curricular content between health professional schools can reduce faculty burden, the literature provides little guidance to support these efforts. The objective of this investigation was to synthesize data from two prior studies to delineate recommendations guiding the future development of shared curricula in health professional education. Applying Rogers’ Diffusion of Innovations Theory as a guiding framework, relevant data were extracted from a two-phase mixed-methods study evaluating the long-term impact of the shared Rx for Change: Clinician-Assisted Tobacco Cessation program. Phase 1, a qualitative study, involved telephone interviews with faculty participants of train-the-trainer workshops conducted between 2003 and 2005. These results informed the development of a phase 2 national survey, administered electronically as a long-term follow-up (13 to 15 years later) with train-the-trainer workshop participants. Results from the two studies were synthesized and summarized, producing seven key recommendations to guide development of shared curricula: (1) appeal to attendees, (2) relate content to clinical practice, (3) deliver live, in-person training, (4) develop high-quality materials, delivered by experts, (5) provide support, (6) meet accreditation standards, and (7) demonstrate effectiveness. Future program developers should consider these recommendations to enhance dissemination, adoption, and long-term sustainability of shared curricular content.

  • Open Access

    Relationship between angiotensin‐converting enzyme inhibitors and angiotensin receptor blockers prescribing and delirium in the ICU‐A secondary analysis

    by Malissa A. Mulkey, Sikandar Khan, Anthony Perkins, Sujuan Gao, Sophia Wang, Noll Campbell, Babar Khan

    Background: Studies suggest Angiotensin‐Converting Enzyme inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) may slow the decline of memory function in individuals with mild to moderate Alzheimer's disease by regulating migroglial activation and oxidative stress within the brain's reticular activating system. Therefore, we evaluated the relationship between delirium prevalence and being prescribed ACEI and ARB in participants admitted to the intensive care units (ICU). Methods: A secondary analysis of data from two parallel pragmatic randomized controlled trials was performed. ACEI and ARB exposure was defined as being prescribed an ACEI or an ARB within six months prior to the ICU admission. The primary endpoint was the first positive delirium assessment based on Confusion Assessment Method for the ICU (CAM‐ICU) for up to thirty days. Results: A total of 4791 patients admitted to the medical, surgical, and progressive ICU and screened for eligibility for the parent studies between February 2009 and January 2015 from two level 1 trauma and one safety net hospital in a large urban academic health system were included. Delirium rates in the ICU were not significantly different among participants with no exposure to ACEI/ARB (12.6%), or exposure to ACEI (14.4%), ARB (11.8%), or ACEI and ARB in combination (15.4%) in six months prior to the ICU admission. Exposure to ACEI (OR = 0.97[0.77, 1.22]), ARB (OR = 0.70 [0.47, 1.05]), or both (OR = 0.97 [0.33, 2.89]) in six months prior to ICU admission was not significantly associated with odds of delirium during the ICU admission after adjusting for age, gender, race, co‐morbidities, and insurance status. Conclusions: While the impact of ACEI and ARB exposure prior to the ICU admission was not associated with the prevalence of delirium in this study, further research is needed to fully understand the impact of antihypertensive medications on delirium.


  • Open Access

    Deprescribing anticholinergics in primary care older adults: Experience from two models and impact on a continuous measure of exposure

    by Noll L. Campbell, Christopher Pitts, Claire Corvari, Ellen Kaehr, Khalid Alamer, Parveen Chand, Kristine Nanagas, Christopher M. Callahan, Malaz A. Boustani

    Background: Deprescribing interventions delivered through the electronic medical record have not significantly reduced the use of high‐risk anticholinergics in prior trials. Pharmacists have been identified as ideal practitioners to conduct deprescribing; however, little experience beyond collaborative consult models has been published.Objective: To evaluate the impact of two pilot pharmacist‐based advanced practice models nested within primary care.Methods: Pilot studies of a collaborative clinic‐based pharmacist deprescribing intervention and a telephone‐based pharmacist deprescribing intervention were conducted. Patients receiving the clinic‐based pharmacy model were aged 55 years and older and referred for deprescribing at a specialty clinic. Patients receiving the telephone‐based pharmacy model were aged 65 years and older and called by a clinical pharmacist for deprescribing without referral. Deprescribing was defined as a discontinuation or dose reduction reported either in clinical records or through self‐reporting.Results: The 18 patients receiving clinic‐based deprescribing had a mean age of 68 years and 78% were female. Among 24 medications deemed eligible for deprescribing, 23 (96%) were deprescribed. The clinic‐based deprescribing model resulted in a 93% reduction in median annualized total standardized dose (TSD), 56% lowered their annualized exposure below a cognitive risk threshold, and 4 (17%) of medications were represcribed within 6 months. The 24 patients receiving telephone‐based deprescribing had a mean age of 73 years and 92% were female. Among 24 medications deemed eligible for deprescribing, 12 (50%) were deprescribed. There was no change in the median annualized TSD, the annualized TSD was lowered below a cognitive risk threshold in 46%, and no medications were represcribed within 6 months. Few withdrawal symptoms or adverse events were reported in both groups.Conclusions: Pharmacist‐based deprescribing successfully reduced exposure to high‐risk anticholinergics in primary care older adults, yet further work is needed to understand the impact on clinical outcomes.


  • Open Access

    Usability-In-Place—Remote Usability Testing Methods for Homebound Older Adults: Rapid Literature Review

    by Jordan R Hill, Janetta C Brown, Noll L Campbell, Richard J Holden

    Background: Technology can benefit older adults in many ways, including by facilitating remote access to services, communication, and socialization for convenience or out of necessity when individuals are homebound. As people, especially older adults, self-quarantined and sheltered in place during the COVID-19 pandemic, the importance of usability-in-place became clear. To understand the remote use of technology in an ecologically valid manner, researchers and others must be able to test usability remotely. Objective: Our objective was to review practical approaches for and findings about remote usability testing, particularly remote usability testing with older adults. Methods: We performed a rapid review of the literature and reported on available methods, their advantages and disadvantages, and practical recommendations. This review also reported recommendations for usability testing with older adults from the literature. Results: Critically, we identified a gap in the literature—a lack of remote usability testing methods, tools, and strategies for older adults, despite this population’s increased remote technology use and needs (eg, due to disability or technology experience). We summarized existing remote usability methods that were found in the literature as well as guidelines that are available for conducting in-person usability testing with older adults. Conclusions: We call on the human factors research and practice community to address this gap to better support older adults and other homebound or mobility-restricted individuals.